RANI
Price:
$2.41
Market Cap:
$135.94M
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatm...[Read more]
Industry
Biotechnology
IPO Date
2021-07-30
Stock Exchange
NASDAQ
Ticker
RANI
According to Rani Therapeutics Holdings, Inc.’s latest financial reports and current stock price. The company's current ROE is -300.92%. This represents a change of 168.23% compared to the average of -112.19% of the last 4 quarters.
The mean historical ROE of Rani Therapeutics Holdings, Inc. over the last ten years is -101.12%. The current -300.92% ROE has changed 197.58% with respect to the historical average. Over the past ten years (40 quarters), RANI's ROE was at its highest in in the December 2020 quarter at 14.74%. The ROE was at its lowest in in the June 2024 quarter at -240.04%.
Average
-101.12%
Median
-111.97%
Minimum
-264.03%
Maximum
27.52%
Discovering the peaks and valleys of Rani Therapeutics Holdings, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 53.62%
Maximum Annual ROE = 27.52%
Minimum Annual Increase = -859.80%
Minimum Annual ROE = -264.03%
Year | ROE | Change |
---|---|---|
2023 | -264.03% | 53.62% |
2022 | -171.87% | 53.49% |
2021 | -111.97% | -859.80% |
2020 | 14.74% | -46.45% |
The current ROE of Rani Therapeutics Holdings, Inc. (RANI) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-182.63%
5-year avg
-101.12%
10-year avg
-101.12%
Rani Therapeutics Holdings, Inc.’s ROE is greater than Vincerx Pharma, Inc. (-276.65%), greater than Tenaya Therapeutics, Inc. (-80.97%), greater than Corvus Pharmaceuticals, Inc. (-53.99%), greater than ALX Oncology Holdings Inc. (-946.88%), greater than Lyra Therapeutics, Inc. (-143.74%), greater than Trevi Therapeutics, Inc. (-49.92%), greater than SQZ Biotechnologies Company (-10.98%), greater than Protara Therapeutics, Inc. (-55.03%), greater than TRACON Pharmaceuticals, Inc. (-237.65%), less than Vaccinex, Inc. (1.11%), greater than Monopar Therapeutics Inc. (-110.60%), greater than Miromatrix Medical Inc. (-119.21%), greater than Surrozen, Inc. (-178.66%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than PMV Pharmaceuticals, Inc. (-21.96%), greater than Pharvaris N.V. (-36.89%), greater than Tyra Biosciences, Inc. (-27.13%), greater than Molecular Partners AG (-33.08%), greater than Cabaletta Bio, Inc. (-43.98%), greater than Viracta Therapeutics, Inc. (-292.12%), greater than EyePoint Pharmaceuticals, Inc. (-43.24%), greater than Biomea Fusion, Inc. (-118.90%),
Company | ROE | Market cap |
---|---|---|
-276.65% | $11.06M | |
-80.97% | $190.12M | |
-53.99% | $564.21M | |
-946.88% | $78.48M | |
-143.74% | $17.21M | |
-49.92% | $220.68M | |
-10.98% | $12.83M | |
-55.03% | $53.43M | |
-237.65% | $136.30K | |
1.11% | $9.06M | |
-110.60% | $87.22M | |
-119.21% | $92.95M | |
-178.66% | $38.09M | |
-70.40% | $542.54M | |
-21.96% | $84.49M | |
-36.89% | $1.29B | |
-27.13% | $865.93M | |
-33.08% | $247.30M | |
-43.98% | $195.39M | |
-292.12% | $7.88M | |
-43.24% | $775.07M | |
-118.90% | $320.35M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Rani Therapeutics Holdings, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Rani Therapeutics Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Rani Therapeutics Holdings, Inc.'s ROE?
How is the ROE calculated for Rani Therapeutics Holdings, Inc. (RANI)?
What is the highest ROE for Rani Therapeutics Holdings, Inc. (RANI)?
What is the 3-year average ROE for Rani Therapeutics Holdings, Inc. (RANI)?
What is the 5-year average ROE for Rani Therapeutics Holdings, Inc. (RANI)?
How does the current ROE for Rani Therapeutics Holdings, Inc. (RANI) compare to its historical average?